|
IeDEA West Africa Renewal 3
|
U01AI069919-12
|
$225,000
|
|
Dabis, Francois
|
ADERA
|
|
Central Africa International Epidemiologic Database to Evaluate AIDS
|
U01AI096299-08
|
$260,000
|
|
ANASTOS, KATHRYN
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, IN
|
|
Methylthioadenosine Phosphorylase and AdoMet Synthetase in Cancer
|
5R01CA135405-10
|
$290,592
|
|
SCHRAMM, VERN
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Proteogenomic Translational Research Center for Clinical Proteomic
|
1U01CA214116-01
|
$1,374,609
|
|
RODLAND, KARIN
|
BATTELLE PACIFIC NORTHWEST LABORATORIES
|
|
Discovering genetic networks of triple-negative breast cancer
|
5R01CA178039-05
|
$324,738
|
|
WESTBROOK, THOMAS
|
BAYLOR COLLEGE OF MEDICINE
|
|
Targeted activation of autoimmune checkpoints in B cell malignancies
|
7R01CA157644-08
|
$410,875
|
$410,875
|
M?SCHEN, MARKUS
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Cancer Center Support Grant
|
3P30CA033572-34S1
|
$73,297
|
$1,466
|
ROSEN, STEVEN
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Cancer Center Support Grant
|
3P30CA033572-34S2
|
$124,999
|
$2,500
|
ROSEN, STEVEN
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Cancer Center Support Grant
|
5P30CA033572-34
|
$2,446,682
|
$48,934
|
ROSEN, STEVEN
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
SOX9 Mediation of AR and ERG Driven Prostate Cancer
|
5R01CA168393-04
|
$361,050
|
|
BALK, STEVEN
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Novel regulation of PI3K/Akt to direct targeted breast cancer therapies
|
5R01CA177910-05
|
$361,050
|
|
TOKER, ALEX
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Exploiting Metabolic Vulnerabilities in the PI3K and Akt Pathway in Cancer for Therapeutic Benefit
|
5R01CA200671-02
|
$395,738
|
|
TOKER, ALEX
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
The role of Jmjd1c in normal and leukemic hematopoiesis
|
5R00CA168996-05
|
$238,701
|
|
ZHU, NAN
|
BLOODCENTER OF WISCONSIN, INC.
|
|
Development of a novel cell-based immune therapy using Nanoparticles and natural IgM-producing phagocytic B cells
|
5R21CA205415-02
|
$186,807
|
|
ZHONG, XUEMEI
|
BOSTON MEDICAL CENTER
|
|
Transforming the diagnosis and care of patients with CTCL using TCR sequencing
|
5R01CA203721-02
|
$680,545
|
|
CLARK, RACHAEL
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
CRISPR/Cas9-based lineage tracing for fate mapping of cancer cells and stem cells
|
5R21CA205825-02
|
$207,365
|
|
LI, ZHE
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Clinical implementation of single cell tumor transcriptome analysis
|
5R33CA202820-02
|
$438,255
|
|
REGEV, AVIV
|
BROAD INSTITUTE, INC.
|
|
PHIP as a Biomarker of Triple-Negative Melanoma
|
5R01CA175768-04
|
$424,835
|
|
KASHANI-SABET, MOHAMMED
|
CALIFORNIA PACIFIC MED CTR RES INSTITUTE
|
|
Lung cancer in never smokers: incidence, risk factors, and molecular characteristics in Asian American, Native Hawaiian and Pacific Islander females
|
5R01CA204070-02
|
$572,056
|
|
GOMEZ, SCARLETT
|
CANCER PREVENTION INSTIT OF CALIFORNIA
|
|
Targeting Brain Tumor Stem Cells In The Hypoxic Microenvironment
|
5R01CA187780-03
|
$385,491
|
|
BAR, ELI
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Case/UHC Center for AIDS Research
|
P30AI036219-23
|
$229,791
|
|
KARN, JONATHAN
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Nanoconjugate delivery of proliferation and checkpoint inhibitors to treat glial tumors
|
5R01CA206220-02
|
$549,102
|
|
LJUBIMOVA, JULIA
|
CEDARS-SINAI MEDICAL CENTER
|
|
Development of a Multi-Panel Multiplex Immunofluorescence Breast Cancer Immunophenotyping Assay
|
5R44CA203278-03
|
$141,450
|
|
SCHWARTZ, DAVID
|
CELL IDX, INC.
|
|
Role of Sialic Acid Modification in ALL Survival and Drug Resistance
|
5R01CA090321-15
|
$266,069
|
|
HEISTERKAMP, NORA
|
CHILDREN'S HOSPITAL OF LOS ANGELES
|
|
Exploiting proteotoxic stress in therapy-refractory HER2+ breast cancers
|
5R01CA193549-03
|
$356,850
|
|
KOMUROV, KAKAJAN
|
CINCINNATI CHILDRENS HOSP MED CTR
|
|
ASSESSING THE THERAPEUTIC WINDOW FOR FUTURE ANTI-NOTCH DIMERIZATION AGENTS
|
5R01CA163653-05
|
$311,165
|
|
KOPAN, RAPHAEL
|
CINCINNATI CHILDRENS HOSP MED CTR
|
|
Targeting Ferritin in Glioblastoma
|
5R01CA169117-05
|
$532,477
|
|
BAO, SHIDENG
|
CLEVELAND CLINIC LERNER COM-CWRU
|
|
Preclinical analyses of advanced prostate cancer in genetically-engineered mice
|
5R01CA173481-05
|
$389,781
|
|
ABATE-SHEN, CORY
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
The mechanisms driving brain oncogenesis by FGFR-TACC gene fusions
|
5R01CA178546-04
|
$366,858
|
|
IAVARONE, ANTONIO
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
The role of the LZTR1 ubiquitin ligase in stem cells and cancer
|
5R01CA190891-03
|
$383,079
|
|
IAVARONE, ANTONIO
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Topology of Cancer Evolution and Heterogeneity
|
5U54CA193313-03
|
$2,087,754
|
|
RABADAN, RAUL
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
(PQA2) Interstitial stiffness as a physicochemical modulator of obesity-induced b
|
5R01CA185293-04
|
$329,104
|
|
FISCHBACH, CLAUDIA
|
CORNELL UNIVERSITY
|
|
Targeting the cytokine circuitry of KRAS-driven lung cancer
|
5R01CA190394-03
|
$394,578
|
|
BARBIE, DAVID
|
DANA-FARBER CANCER INST
|
|
Genetic evolution of glioblastomas during radiation and temozolomide therapy
|
5R01CA188228-03
|
$689,449
|
|
BEROUKHIM, RAMEEN
|
DANA-FARBER CANCER INST
|
|
Stroma-mediated clonal evolution in Multiple Myeloma
|
5R01CA181683-04
|
$353,770
|
|
GHOBRIAL, IRENE
|
DANA-FARBER CANCER INST
|
|
Development of covalent PIP4K2 inhibitors for the treatment of p53 deficient lung tumors
|
5R01CA197329-03
|
$540,936
|
|
GRAY, NATHANAEL
|
DANA-FARBER CANCER INST
|
|
Intratumor heterogeneity underlying treatment resistance in HER2+ breast tumors
|
5U01CA195469-03
|
$666,735
|
|
POLYAK, KORNELIA
|
DANA-FARBER CANCER INST
|
|
Functional analysis of the Tip60 complex
|
5R01CA093602-13
|
$311,400
|
|
PRICE, BRENDAN
|
DANA-FARBER CANCER INST
|
|
The function of cyclin C in tumorigenesis
|
5R01CA190509-03
|
$453,569
|
|
SICINSKI, PETER
|
DANA-FARBER CANCER INST
|
|
Super-Localization Ultrasound Imaging with Targeted Laser-activated Nanodetectors
|
5R21CA197409-02
|
$211,410
|
|
LUKE, GEOFFREY
|
DARTMOUTH COLLEGE
|
|
Structured Light Scatteroscopy for Intraoperative Breast Tumor Margin Assessment
|
5F31CA196308-02
|
$44,044
|
|
MCCLATCHY III, DAVID
|
DARTMOUTH COLLEGE
|
|
Using CRISPR/Cas9 to dissect the role of FUS-CHOP in tumor response to radiation therapy
|
5F30CA206424-02
|
$37,644
|
|
CHEN, MARK
|
DUKE UNIVERSITY
|
|
Designing durable apoptosis-targeting therapies for acute myeloid leukemia
|
5F30CA206348-02
|
$34,765
|
|
LIN, KEVIN
|
DUKE UNIVERSITY
|
|
Molecular Mechanisms of G5-7 Allosteric Inhibition of Jak2
|
5R01CA186918-03
|
$356,850
|
|
YE, KEQIANG
|
EMORY UNIVERSITY
|
|
The PDX Integrator- Re-purposing KOMP2 informatics to widely disseminate data from Patient Derived Xenografts
|
5U24CA204781-02
|
$383,503
|
|
PARKINSON, HELEN
|
EUROPEAN MOLECULAR BIOLOGY LABORATORY
|
|
Training Program in Research Ethics in the Americas
|
R25TW001605-18
|
$45,706
|
|
LUNA, FLORENCIA
|
FACULTAD LATINOAMERICANA DE CIENCIAS SOC
|
|
IeDEA Asia-Pacific Research Collaboration
|
U01AI069907-12
|
$260,000
|
|
SOHN, ANNETTE
|
FOUNDATION FOR AIDS RESEARCH
|
|
Estimating Overdiagnosis in Cancer Screening Studies
|
5R01CA192402-03
|
$614,029
|
|
ETZIONI, RUTH
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
Molecular pathoepidemiology of contralateral breast cancer
|
1R01CA206464-01A1
|
$1,438,154
|
|
MALONE, KATHLEEN
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
District of Columbia Center for AIDS Research (DC CFAR)
|
P30AI117970-03
|
$210,140
|
|
Greenberg, Alan
|
GEORGE WASHINGTON UNIVERSITY
|
Total relevant funding to Autoimmune Diseases for this search: $8,128,980
|